FDA Brief

Warning letters Devices

FDA warning letter to

Next Medical Products Company, LLC

High riskIssued Aug 19Posted Nov 3Center for Devices and Radiological Health

FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

What happened

FDA inspected the Branchburg, NJ plant from November 10 to December 10, 2025 and reviewed the firm's written replies. Investigators found the company ignored repeated high microbial counts in its gel packaging areas, never opened corrective actions, made label and formula changes without verification, and shipped Clear Image and MediChoice gel contaminated with Paraburkholderia (a bacterium) that CDC confirmed. The firm told customers on 07/23/2025 to return or discard the gel but never filed the required FDA report, and its 2024 preservative change was never cleared by FDA.

What FDA found

  1. The environmental testing procedure let the company throw out failed microbial results by simply re-testing, with no investigation and no written justification.

    21 CFR 820.70(c)
  2. The chosen sampling spots were never shown to be worst case, and the procedure never defined what counts as a significant finding, so a result of 25,000 or more CFUs (colony forming units, a count of microbes) led to no extra testing.

    21 CFR 820.70(c)
  3. The corrective and preventive action (CAPA) procedure did not list all the quality data the firm should review, so no CAPA was opened after repeated failed environmental counts or after lab samples sat for days before shipping.

    21 CFR 820.100(a)
  4. A new label insert adding contraindications after a CDC safety concern, and a change of preservative in the gel formula, were made without design verification or validation.

    21 CFR 820.30(i)
  5. The firm did not send FDA a report of correction or removal within 10 working days after it contacted customers on 07/23/2025 about contaminated gel.

    21 CFR 806.10
  6. The 2024 switch to a new preservative changed the device's material formulation in a way that could affect safety or effectiveness, but the firm did not submit a new 510(k) premarket notification.

    21 CFR 807.81(a)(3)(i); section 501(f)(1)(B) and 502(o) of the Act

What FDA wants

FDA tells the firm to reply in writing within fifteen business days describing the steps taken, how it will prevent repeat violations, and a timetable for any work still to come, sent to CDRHEnforcement@fda.hhs.gov with the subject line "CMS Case 727918". FDA also says the firm must submit the missing correction/removal report and address the uncleared device change.

Who should pay attention

  • hospitals and clinics that buy or use ultrasound gel
  • companies that pack or fill non-sterile gels for other brands
  • makers of cleared devices planning formula or labeling changes

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk
  4. Rohto Pharmaceutical Co., Ltd.

    FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.

    High risk